---
title: "Why This Top-Ranked IBD 50 Stock Just Plummeted On Its Earnings"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295015731.md"
description: "Exelixis saw a sharp decline in its stock late Wednesday following the release of its second-quarter results, which were a mixed bag. This top-ranked IBD 50 stock witnessed a significant drop in value after its earnings report."
datetime: "2026-08-05T20:46:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295015731.md)
  - [en](https://longbridge.com/en/news/295015731.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295015731.md)
generator: "portal-rs"
---

# Why This Top-Ranked IBD 50 Stock Just Plummeted On Its Earnings

Exelixis saw a sharp decline in its stock late Wednesday following the release of its second-quarter results, which were a mixed bag. This top-ranked IBD 50 stock witnessed a significant drop in value after its earnings report.

### Related Stocks

- [EXEL.US](https://longbridge.com/en/quote/EXEL.US.md)

## Related News & Research

- [UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Decreases Stock Position in Exelixis, Inc. $EXEL](https://longbridge.com/en/news/297887944.md)
- [What is Zacks Research's Estimate for Exelixis Q4 Earnings?](https://longbridge.com/en/news/298028129.md)
- [Allianz Asset Management GmbH Decreases Holdings in Exelixis, Inc. $EXEL](https://longbridge.com/en/news/298276045.md)
- [STTK: DR3 blockade targets durable, low-immunogenicity IBD therapy with pivotal data expected in 2028](https://longbridge.com/en/news/298348199.md)
- [Exelixis wins appeals court ruling upholding key patents, FDA approval barred until at least Jan 15, 2030](https://longbridge.com/en/news/297558356.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**